6-fluoromevalonolactone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

6-Fluoromevalonolactone is a synthetic analog of mevalonolactone, a key intermediate in the biosynthesis of cholesterol and other isoprenoids. It acts as a potent inhibitor of hydroxymethylglutaryl-CoA reductase (HMG-CoA reductase), the rate-limiting enzyme in cholesterol biosynthesis. Due to its ability to block cholesterol synthesis, 6-fluoromevalonolactone has been investigated as a potential therapeutic agent for hypercholesterolemia and other cardiovascular diseases. The compound has also been studied for its potential anti-inflammatory and anti-cancer properties. Synthesis of 6-fluoromevalonolactone typically involves fluorination of mevalonolactone or a suitable precursor. The compound is often used in research to study the regulation of cholesterol biosynthesis and the effects of HMG-CoA reductase inhibition.'
```

Cross-References

ID Source	ID
PubMed CID	119214
CHEMBL ID	3185156
CHEBI ID	125368
MeSH ID	M0131500

Synonyms (20)

Synonym
4-(fluoromethyl)tetrahydro-4-hydroxy-2h-pyran-2-one
6-fluoromevalonate, >=90% (gc), viscous liquid
NCGC00165794-01
fluoromevalonate
CHEBI:125368
2822-77-7
4-(fluoromethyl)-4-hydroxyoxan-2-one
AKOS006285000
2h-pyran-2-one, 4-(fluoromethyl)tetrahydro-4-hydroxy-
6-fmva
6-fluoromevalonate
6-fluoromevalonolactone
zr 3516
BRD-A12426960-001-01-6
CHEMBL3185156
4-(fluoromethyl)-4-hydroxy-2-oxanone
Q27215723
J-017007
CS-0135985
HY-133957

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

Class	Description
delta-lactone	A lactone having a six-membered lactone ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Potency Measurements

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE	Homo sapiens (human)	Potency	1.0000	0.0032	45.4673	12,589.2998	AID2517
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	2 (22.22)	18.7374
1990's	6 (66.67)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (11.11)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.27

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	12.27 (24.57)
Research Supply Index	2.40 (2.92)
Research Growth Index	4.66 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (12.27)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	10 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
isopentenyl pyrophosphate isopentenyl pyrophosphate: substrate for isopentenyl pyrophosphate isomerase; RN given refers to unlabeled cpd; a nonpeptide mycobacterial antigen that stimulates gamma delta T cells. isopentenyl diphosphate : A prenol phosphate comprising 3-methylbut-3-en-1-ol having an O-diphosphate substituent.	1.96	1	prenol phosphate	antigen; antioxidant; epitope; Escherichia coli metabolite; mouse metabolite; phosphoantigen
pamidronate [no description available]	2.06	1	phosphonoacetic acid
thymidine [no description available]	1.98	1	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; metabolite; mouse metabolite
cantharidin Cantharidin: A toxic compound, isolated from the Spanish fly or blistering beetle (Lytta (Cantharis) vesicatoria) and other insects. It is a potent and specific inhibitor of protein phosphatases 1 (PP1) and 2A (PP2A). This compound can produce severe skin inflammation, and is extremely toxic if ingested orally.. cantharidin : A monoterpenoid with an epoxy-bridged cyclic dicarboxylic anhydride structure secreted by many species of blister beetle, and most notably by the Spanish fly, Lytta vesicatoria. Natural toxin inhibitor of protein phosphatases 1 and 2A.	1.96	1	cyclic dicarboxylic anhydride; monoterpenoid	EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; herbicide
thiophenes Thiophenes: A monocyclic heteroarene furan in which the oxygen atom is replaced by a sulfur.. thiophenes : Compounds containing at least one thiophene ring.	1.99	1	mancude organic heteromonocyclic parent; monocyclic heteroarene; thiophenes; volatile organic compound	non-polar solvent
lovastatin Lovastatin: A fungal metabolite isolated from cultures of Aspergillus terreus. The compound is a potent anticholesteremic agent. It inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It also stimulates the production of low-density lipoprotein receptors in the liver.. lovastatin : A fatty acid ester that is mevastatin carrying an additional methyl group on the carbobicyclic skeleton. It is used in as an anticholesteremic drug and has been found in fungal species such as Aspergillus terreus and Pleurotus ostreatus (oyster mushroom).	2.9	4	delta-lactone; fatty acid ester; hexahydronaphthalenes; polyketide; statin (naturally occurring)	anticholesteremic drug; antineoplastic agent; Aspergillus metabolite; prodrug
zoledronic acid Zoledronic Acid: An imidobisphosphonate inhibitor of BONE RESORPTION that is used for the treatment of malignancy-related HYPERCALCEMIA; OSTEITIS DEFORMANS; and OSTEOPOROSIS.. zoledronic acid : An imidazole compound having a 2,2-bis(phosphono)-2-hydroxyethane-1-yl substituent at the 1-position.	2.06	1	1,1-bis(phosphonic acid); imidazoles	bone density conservation agent
mevalonic acid Mevalonic Acid: A dihydroxy monocarboxylic acid and precursor in the biosynthetic pathway known as the mevalonate pathway, which produces terpenes and steroids that are vital for diverse cellular functions.. mevalonic acid : A racemate composed of equimolar amounts of (R)- and (S)-mevalonic acid.. (R)-mevalonic acid : The (R)-enantiomer of mevalonic acid.	3.59	9	3,5-dihydroxy-3-methylpentanoic acid
5-diphosphomevalonic acid 5-diphosphomevalonic acid: RN given refers to ion(1-). (R)-5-diphosphomevalonic acid : The 5-diphospho derivative of (R)-mevalonic acid.	2.38	2	carboxyalkyl phosphate	human metabolite; mouse metabolite
squalestatin 1 squalestatin 1: structure given in first source; inhibits both mammalian and fungal squalene synthetase; from fungus Phoma sp (Coelomycetes). zaragozic acid A : A polyketide isolated from fungi that is a potent inhibitor of fungal and mammalian squalene synthase.	2.42	2	acetate ester; cyclic ketal; oxabicycloalkane; polyketide; tertiary alcohol; tricarboxylic acid	EC 2.5.1.21 (squalene synthase) inhibitor; fungal metabolite
nb 598 NB 598: decreases serum total & LDL-cholesterol levels; structure given in first source; inhibits squalene epoxidase	1.99	1

Condition	Relationship Strength	Studies
Bladder Cancer [description not available]	1.98	1
Cell Transformation, Neoplastic Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.	1.98	1
Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER.	1.98	1
Hepatocellular Carcinoma [description not available]	1.99	1
Cancer of Liver [description not available]	1.99	1
Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	1.99	1
Liver Neoplasms Tumors or cancer of the LIVER.	1.99	1

chemdatabank.com